

Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. *Blood Adv.* 2023;7(23):7270-7278.

Page 7273: in [Table 1](#) under “Survivors N = 204,” in the row “Diagnosed with second malignancy,” the value should read “48 (24.0),” not “51 (25.0).” The corrected [Table 1](#) is shown below:

Table 1. Characteristics of survivors of HL and community controls

	Survivors	Controls	P value
	N = 204	N = 205	
	n (%)	n (%)	
Sex			
Male	97 (47.5)	99 (48.3)	0.88
Female	107 (52.5)	106 (51.7)	
Race			
White	172 (84.3)	176 (85.9)	0.66
Other	32 (15.7)	29 (14.1)	
Smoking Status			
Current	39 (19.1)	29 (14.3)	0.37
Former	35 (17.2)	41 (20.2)	
Never	130 (63.7)	133 (65.5)	
Body mass index			
Underweight	7 (3.4)	3 (1.5)	0.23
Normal weight	51 (25.0)	62 (30.2)	
Overweight	73 (35.8)	60 (29.3)	
Obese	73 (35.8)	80 (39.0)	
Age at assessment (y)	Mean (SD)		
	36.6 (8.01)	36.7 (9.17)	0.84
	Median (min-max)		
Age at diagnosis (y)	14.7 (3.0-22.6)		
Time since diagnosis (y)	20.6 (10.7-45.6)		
Anthracyclines (n = 156) mg/m ²	157.2 (91.0-400.0)*		
IV methotrexate (n = 85) mg/m ²	123.2 (20.3-167.7)		
Bleomycin (n = 58) mg/m ²	35.6 (5.0-95.0)		
Corticosteroids (n = 140) mg/m ²	2240 (250-4480)		
Vincristine (n=182) mg/m ²	45.9 (9.2-151.2)		
Cyclophosphamides (n=113) mg/m ²	3655 (1332-22 889)†		
Chest Radiation (n=204) Gy	26.0 (15.0-45.0)		
Neck Radiation (n=204) Gy	26.0 (15.0-51.0)		
	N (%)		
Relapsed	14 (6.9)		
Diagnosed with second malignancy	48 (24.0)		

Max, maximum; min, minimum; SD, standard deviation.

*Anthracycline equivalent dose.

†Cyclophosphamide equivalent dose.

Page 7274: in Table 2 under the “Survivors Mean (SD)” and “Controls Mean (SD)” columns, the authors misreported the means and standard deviations of the neurocognitive test at the hundredth decimal place. The corrected Table 2 is shown below:

Table 2. Mean age-adjusted neurocognitive z scores of survivors and controls

Domain	Survivors	Controls	FDR <i>P</i>
	Mean (SD)	Mean (SD)	
Attention			
Focused	0.35 (0.95)	0.54 (0.84)	0.061
Span	0.04 (1.01)	0.22 (0.92)	0.085
Sustained	-0.10 (1.35)	0.23 (0.89)	0.011
Variability	-0.23 (1.11)	-0.03 (1.05)	0.089
Processing Speed			
Reaction time	-0.16 (1.17)	-0.04 (0.99)	0.29
Visuomotor	0.13 (0.96)	0.40 (0.94)	0.011
Visual	0.27 (0.98)	0.62 (0.97)	0.002
Motor	-0.38 (1.05)	-0.01 (0.90)	0.001
Memory			
Verbal learning	-0.08 (1.04)	0.31 (1.02)	0.001
Short-term recall	-0.24 (1.01)	0.12 (1.04)	0.002
Long-term recall	-0.30 (1.14)	0.08 (1.10)	0.002
Selective reminding	-0.18 (1.11)	-0.03 (0.96)	0.17
Executive Function			
Working memory	-0.08 (0.93)	0.05 (0.86)	0.16
Self-monitoring	-0.00 (1.14)	0.20 (0.95)	0.085
Cognitive flexibility	-0.02 (1.26)	0.26 (1.11)	0.033
Fluency	-0.05 (1.20)	0.03 (1.05)	0.47

Means and SDs presented as age-adjusted z scores, with population mean = 0 and SD = 1.0.
 FDR, *P*, false discovery rate-adjusted *P*-values for multiple comparisons between survivors and control; SD, standard deviation.

These errors do not impact the *P* values, statistical significance, or relevant interpretations of the data.

<https://doi.org/10.1182/bloodadvances.2024013111>

© 2024 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](https://creativecommons.org/licenses/by-nc-nd/4.0/), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Downloaded from <http://ashpublications.net/bloodadvances/article-pdf/8/10/2398/2226488/bloodadv-2024-013111-main.pdf> by guest on 08 June 2024